ABSTRACT
Background Type 2 diabetes (DM2) is a leading cause of premature morbidity and mortality globally and affects more than 100 million people in the world’s most populous country, India. Nutrition is a critical and evidence-based component of effective blood sugar control and most dietary advice emphasizes carbohydrate and calorie reduction. Emerging global evidence demonstrates marked inter-individual differences in post-prandial glucose response (PPGR) although no such data exists in India and prior studies have primarily evaluated PPGR variation in individuals without diabetes.
Methods This prospective cohort study seeks to characterize the PPGR variability in Indians with diabetes and to identify factors associated with these differences. Adults with type 2 diabetes and a hemoglobin A1c ≥7 are being enrolled from 14 sites around India. Subjects wear a continuous glucose monitor, eat a series of standardized meals, and record all free-leaving foods, activities, and medication use for a 14-day period. The study’s primary outcome is PPGR, calculated as the incremental area under the curve 2 hours after each logged meal.
Discussion This study will provide the first large scale examination variability in blood sugar responses to food in India and will be among the first to estimate PPGR variability for individuals with DM2 in any jurisdiction. Results from our study will generate data to facilitate the creation of machine learning models to predict individual PPGR responses and to facilitate the prescription of personalized diets for individuals with DM2.
Competing Interest Statement
Dr. Choudhry and Mr. Swamy receive consulting fees and hold equity in Decipher Health. Dr. Priyadarshini is an employee of Decipher Health. Dr. Mehta is an employee and holds equity in Decipher Health.
Funding Statement
This study was funded by Decipher Health
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the ethics committees at all institutions enrolling patients. In specific: Dia Care Diabetes Hormone Clinic, Ahmedabad; Inamdar Multi-Specialty Hospital, Pune; Renova Neelima Hospital, Hyderabad; Bhandari Clinic and Research Centre, Jaipur; Maharaja Agrasen Hospital, New Delhi; GSVM medical College, Kanpur; MAGJ Hospital, Ernakulam; Bangalore Diabetes Centre and Diagnostic Lab, Bengaluru; Dayanand Medical College and Hospital, Ludhiana; Meenakshi Multi-Specialty Hospital, Chennai; Sparsh Hospital and Critical Care, Bhubaneshwar; Medical College, Kolkata; Downtown Hospital, Guwahati; CHL Hospitals, Indore
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
